Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03098433 · ClinicalTrials.gov registry record · Phase 1
Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
A Phase 1 study of Healthy, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03098433: Completed Phase 1 study of Healthy, sponsored by Virginia Commonwealth University.
NCT03098433 is a Phase 1 study of Healthy that has completed, run by Virginia Commonwealth University. The registered enrollment target is 22 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03098433, a Phase 1 study of Healthy, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the short term effects of a single dose of liothyronine on the cardiovascular system and energy expenditure
Primary Outcome
Cardiac output measured by Echocaridogram, Difference in Stroke Volume Pre- and Post- Drug Administration
Conditions Studied
Interventions
- DRUG Placebos
- DRUG Levothyroxine
- DRUG Liothyronine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2019-06-24 |
| Phase | Phase 1 |
What the finished NCT03098433 record still lists
NCT03098433 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebos is the first listed.
NCT03098433 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03098433 about?
NCT03098433 is a clinical study titled "Effects of Liothyronine on Energy Expenditure and Cardiovascular Function". This study will assess the short term effects of a single dose of liothyronine on the cardiovascular system and energy expenditure
What is the current status of trial NCT03098433?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-10-20. Estimated completion is 2019-06-24.
What conditions does trial NCT03098433 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT03098433?
The interventions under investigation include: Placebos (DRUG), Levothyroxine (DRUG), Liothyronine (DRUG).
Who is sponsoring clinical trial NCT03098433?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03098433 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03098433's enrollment target sits among peer trials
22 844th of 1090 higher than 235 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI